Takeshi Shimamura, Ph.D.
Affiliations: | 2002 | Western Michigan University, Kalamazoo, MI, United States |
Area:
Molecular Biology, Cell BiologyGoogle:
"Takeshi Shimamura"Parents
Sign in to add mentor| Bruce Bejcek | grad student | 2002 | Western Michigan University | |
| (Roles and regulation of NF-kappaB in platelet -derived growth factor transformed cells.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pulido I, Ollosi S, Aparisi S, et al. (2020) Endothelin-1-mediated Drug Resistance in EGFR-mutant NSCLC. Cancer Research |
| Pulido I, Becker J, Aupi M, et al. (2018) Abstract LB-099: Metabolic vulnerabilities of mesenchymal-like EGFR-mutant NSCLC cells with acquired resistance to tyrosine kinase inhibitors Cancer Research. 78 |
| Becker JH, Kahle MP, Soucheray M, et al. (2018) Abstract LB-085: A new role for LKB1 to regulate Heat Shock Protein 90 activity Cancer Research. 78 |
| Ollosi SL, Soucheray M, Becker J, et al. (2018) Abstract 20: Inhibition of mutant EGFR in NSCLC promotes endothelin-1-mediated NSCLC disease progression and angiogenesis Cancer Research. 78: 20-20 |
| Rusan M, Li K, Li Y, et al. (2017) Suppression of adaptive responses to targeted cancer therapy by transcriptional repression. Cancer Discovery |
| Shimamura T. (2016) Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Response. Cancer Research. 76: 3111 |
| Koyama S, Akbay EA, Li YY, et al. (2016) STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T cell activity in the lung tumor microenvironment. Cancer Research |
| Repellin CE, Eser PO, Capelletti M, et al. (2016) Abstract 890: TGFâ upregulation mediates growth retardation in EGFR T790M mutant non-small cell lung cancer Cancer Research. 76: 890-890 |
| Soucheray M, Capelletti M, Pulido I, et al. (2015) Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Research |
| Soucheray M, Capelletti M, Pulido I, et al. (2015) Abstract 766: Suppression of gefitinib-induced EMT in EGFR mutant NSCLC preferentially selects for acquired T790M Cancer Research. 75: 766-766 |